Open an account

Rallybio

RLYB · NASDAQ

$16.38+$0.03 (+0.18%)TodayMarket closed ·
Prev close $16.35

About RLYB

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 14 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Employees
14
Headquarters
New Haven, Connecticut
Listed
Jul 29, 2021
Sector
Health Care
Industry
Biotechnology
Website
rallybio.com

RLYB key statistics

Market cap
87.02M
Price-earnings ratio
2.06
Dividend yield
—
Average volume
8.29K
Volume
102.64K
Open price
$16.48
High today
$16.48
Low today
$16.36
52 Week high
$17.57
52 Week low
$3.67

Rallybio (RLYB) at a glance

Rallybio (RLYB) last traded at $16.38, with a market cap of 87.02M and a price-to-earnings ratio of 2.06.

Today the stock has traded between $16.36 and $16.48. The current price is 0.1% above the day's low and 0.6% below its high.

Volume so far is 102.64K shares, above the average of 8.29K shares a day.

Over the past year Rallybio has ranged from $3.67 to $17.57, and now sits 91% of the way up that range.

Rallybio met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q1 FY26 it reported -$1.46 per share against an estimate of -$1.22.

RLYB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 18.3% on average.

  1. Q2 FY24: reported -$2.96 per share against an estimate of -$3.05
  2. Q3 FY24: reported -$2.08 per share against an estimate of -$2.88
  3. Q4 FY24: reported -$2.00 per share against an estimate of -$2.34
  4. Q1 FY25: reported -$1.68 per share against an estimate of -$2.12
  5. Q2 FY25: reported -$1.76 per share against an estimate of -$2.00
  6. Q3 FY25: reported -$1.12 per share against an estimate of -$1.75
  7. Q4 FY25: reported -$1.03 per share against an estimate of -$1.20
  8. Q1 FY26: reported -$1.46 per share against an estimate of -$1.22

RLYB news

  • Press releasePRNewswire

    Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB

  • Press releasePRNewswire

    Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

  • Press releasePRNewswire

    Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders

  • Press releaseBusiness Wire

    RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders

  • Press releaseBusiness Wire

    Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

  • Press releasePRNewswire

    Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

Similar companies

Companies in the same industry as Rallybio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.